Press Releases

The use of Apica's innovative transapical access technology was successfully demonstrated for the first time at the 27th European Association for Cardio-Thoracic Surgery (EACTS) congress in Vienna. EACTS is one of the largest cardiac congress in the world, with around 6,500 participants.

Medtronic, Inc. (NYSE:MDT) today announced FDA approval of its Lead Integrity Alert (LIA) software for use with non-Medtronic leads. Proprietary and exclusive software that resides in Medtronic defibrillators, LIA is now approved to report performance issues on Durata® and Riata® defibrillator leads (St. Jude Medical) and Endotak® (Boston Scientific) defibrillator leads when connected to a Medtronic device.

Veniti(TM), Inc. (Veniti), has received approval to CE Mark the Veniti Vici(TM) Venous Stent, specifically designed for the treatment of venous obstruction. In addition, the company received CE Mark approval for their varicose vein ablation product, the Veniti Veni(TM) RF Plus Ablation System. The CE Marks allow Veniti to sell products within the European Union.

Neovasc Inc. (TSXV: NVC) today reported topline results for its COSIRA trial assessing the efficacy and safety of the Neovasc ReducerTM, a novel percutaneous device for the treatment of refractory angina. The data shows that the Reducer achieved its primary endpoint, significantly improving the symptoms and functioning of patients disabled by previously untreatable refractory angina. The COSIRA trial also confirmed that the Reducer is safe and well-tolerated, with no reports of device-related serious adverse events. The safety and efficacy data from the randomized, controlled COSIRA trial is consistent with results seen in previous non-randomized pilot studies of the Reducer.

Acusphere, Inc. (ACUSD.PK) today announced that William I. Ramage, D. Phil., has been appointed Chief Development Officer of the Company. Acusphere is focused on the development of Imagify™ (Perflubutane Polymer Microspheres for Injectable Suspension), which if approved for sale, will be a novel cardiovascular drug for the detection of coronary artery disease (CAD), the leading cause of death in the United States and Europe.

Senior nurse for speciality medicine Audrey Kirby was named Nurse Leader of the Year and the heart failure team came home with the Cardiovascular Service Award.

Medtronic, Inc. (NYSE: MDT), announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) allowing the company to initiate SYMPLICITY HTN-4, the first randomized trial to investigate renal denervation for the treatment of moderate uncontrolled hypertension in U.S. patients. 

Memorial is pleased to announce the formation of a unique partnership with one of the area’s most well known centers for cardiovascular care – The Heart Institute of East Texas.

BIOTRONIK announced today that the PK Papyrus covered coronary stent system has received CE mark for the treatment of acute coronary artery perforation.

Novartis today announced the winners of its Mobile Health (mHealth) Challenge, a competition for developers and mobile technology start-ups to participate in creating mobile solutions that can positively impact the lives of caregivers and their loved ones with heart failure. The intensive two-day Challenge brought individuals and teams together to compete for cash prizes totaling $40,000.

OrbusNeich today announced that new clinical data presented at TCT 2013 show durable outcomes as well as excellent early healing and optimal neointimal suppression out to 24 months following placement of the COMBO Dual Therapy Stent. These results from the EGO-COMBO Study were presented by Stephen W.L. Lee, M.D., of the Queen Mary Hospital, University of Hong Kong, China, at the annual interventional cardiology conference in San Francisco.

A healthy weight is the key to a healthy heart, and yet an estimated 1 out of 3 children is either overweight or obese in the U.S. During a special symposium Oct. 27 at the American Academy of Pediatrics National Conference and Exhibition in Orlando, pediatricians discussed obesity and cardiovascular risk factors, public health policy, and how physicians can partner with families to improve children's weight.

Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Lotus™ Valve System, the company's advanced transcatheter aortic valve replacement (TAVR) technology.  This key approval offers a unique and effective new treatment alternative for patients with severe aortic stenosis at high risk with surgical valve replacement.

AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced EU CE Mark approval for its AngioVac venous drainage cannula and cardiopulmonary bypass circuit for use during extracorporeal bypass for up to six hours. Under the CE Mark approval the AngioVac cannula is also approved for removal of fresh, soft thrombi or emboli.

Micell Technologies, Inc. today announced that imaging and clinical results from the DESSOLVE I and DESSOLVE II trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES®) were presented at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference held in San Francisco, October 27 – November 1, 2013. The MiStent SES is a thin-strut drug-eluting stent distinguished by a rapidly absorbable coating designed to control drug release, and which was developed to optimize vessel healing in patients with coronary artery disease.

An overview of coronary artery anatomy will be reviewed in a live, interactive format that simulates clinical practice.

Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery disease, announced today that its TVC Imaging System™ for the true vessel characterization of coronary artery disease will be highlighted in 13 presentations during the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT 2013). TCT 2013, the world's largest educational meeting specializing in interventional cardiovascular medicine, will be held October 27-November 1, 2013 at The Moscone Center in San Francisco.

Corindus Vascular Robotics<http://www.corindus.com/>, the leader in precision vascular robotics, will showcase its FDA-approved CorPath System at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) 2013 annual meeting, Oct. 27 - Nov. 1 in San Francisco, CA. The CorPath is the first medical device to bring robotic precision and accuracy to coronary angioplasty to help optimize clinical outcomes. Experts from renowned hospitals and healthcare organizations across the country will deliver onsite presentations and answer questions about their clinical experience with robotic-assisted angioplasty and the significant advantages in stent precision and clinical outcomes utilizing the CorPath System.

Biosensors International is celebrating a year of significant achievement with an expanded product portfolio, offering physicians a broader range of treatment options to improve patient outcomes.

BIOTRONIK Japan has announced enrollment of the first patient in the BIOFLOW-IV study, which aims to verify the efficacy and safety of the Orsiro Hybrid Drug-Eluting Stent (DES) from BIOTRONIK. The high quality and efficacy of Orsiro has already been confirmed by three important trials, BIOFLOW-I, -II, and –III, which demonstrated the safety and efficacy of Orsiro.

Newly accredited St. Joseph's Hospital Health Center, Syracuse N.Y., is the first hospital in New York and the second in the United States to accomplish accreditation in all three cardiovascular quality disciplines with the Accreditation for Cardiovascular Excellence (ACE): Diagnostic Cath, PCI and Carotid Artery Stenting (CAS), and is only one of two hospitals in New York State to achieve ACE accreditation distinction.